摘要
目的:探讨曲妥珠单抗联合TP化疗对乳腺癌术后影响。方法:选取2014年1月至2016年1月收治的100例乳腺癌患者,按随机数字表法分为对照组和观察组,各50例。术前对照组采用单一TP化疗方案,观察组实施曲妥珠单抗联合TP治疗方案。对比两组患者的疗效、生存质量及不良反应发生率,并对比患者血清因子水平的变化。结果:观察组总有效率为86%(43/50),明显高于对照组的76%(38/50)(P<0.05)。治疗后,观察组的生活质量评分明显高于对照组,血管生成因子VEGFA、VEGFB及VEGFC明显低于对照组(P<0.05)。术后3、6个月,两组患者的不良反应发生率差异无统计学意义(P>0.05)。结论:术前采用曲妥珠单抗联合TP化疗治疗乳腺癌,能改善患者的生活质量,提高患者的短期治疗效果。
Objective： To explore the effect of trastuzumab combined with TP chemotherapy on postoperative breast cancer. Methods： 100 cases of breast cancer patients were randomly selected in our hospital from January2014 to January 2016,and randomly divided into control group and observation group,50 cases in each group. The control group was treated with a single TP chemotherapy regimen,and the observation group was treated with trastuzumab combined with TP chemotherapy. The curative effect,quality of life and incidence of adverse reactions were compared between the two groups after treatment,and the changes of serum factors were compared. Results：The total effective rate of the observation group was 86%（ 43/50）,which was significantly higher than that of the control group（ 38/50,P〈0. 05）. After treatment,the quality of life score of the observation group was significantly higher than that of the control group,and the angiogenic factors VEGFA,VEGFB and VEGFC were significantly lower than those of the control group（ P〈0. 05）. After 3 and 6 months,there was no significant difference in the incidence of adverse reactions between the two groups（ P〉0. 05）. Conclusion： Preoperative use of trastuzumab combined with TP chemotherapy in the treatment of breast cancer can improve the quality of life of the patients and improve the short-term therapeutic effect of the patients.
作者
庹有林
TUO Youlin(Department of Breast, Sichuan Provincial People＇s Hospital, Chengdu 610000, Chin)
出处
《现代医学》
2018年第5期537-540,共4页
Modern Medical Journal
关键词
曲妥珠单抗
TP化疗
乳腺癌
相关指标
影响
trastuzumab
TP chemotherapy
breast cancer
related indicators
impact
